MACI (Vericel Corporation)


Welcome to the PulseAid listing for the MACI drug offered from Vericel Corporation. This Autologous Cultured Cell [EPC],Cells, Cultured, Autologous [Chemical/Ingredient],Chondrocytes [Chemical/Ingredient] pharmaceutical is classified as a CELLULAR THERAPY. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same CELLULAR THERAPY drug type category.
LABELER NAME / MANUFACTURER: Vericel Corporation
NON-PROPRIETARY NAME: autologous cultured chondrocytes
SUBSTANCE NAME: AUTOLOGOUS CULTURED CHONDROCYTES; PORK COLLAGEN
TYPE: CELLULAR THERAPY
PHARMA CLASS: Autologous Cultured Cell [EPC],Cells, Cultured, Autologous [Chemical/Ingredient],Chondrocytes [Chemical/Ingredient]
ROUTE: INTRA-ARTICULAR
DOSAGE FORM: IMPLANT
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2017-01-11
END MARKETING DATE: 0000-00-00


MACI CELLULAR THERAPY Details:

Item DescriptionMACI from Vericel Corporation
LABELER NAME: Vericel Corporation
DEA SCHEDULE:
ACTIVE STRENGTH: 15000000; 15(1/1; cm2/1)
START MARKETING DATE: 2017-01-11
END MARKETING DATE: 0000-00-00
PRODUCT ID: 69866-1030_a6afee99-4a95-4488-84d8-7bdea7e9bbe3
PRODUCT NDC: 69866-1030
APPLICATION NUMBER: BLA125603

Other AUTOLOGOUS CULTURED CHONDROCYTES; PORK COLLAGEN Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Vericel CorporationMACI